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Aims: The effects of biologics on reproduction/lactation are mostly unknown
although many patients that receive biologics are women of reproductive age. The
first objective of this study was to investigate the publicly available data on pre-
gnancy/lactation before and after marketing authorization in Europe of biologics
for the indications of rheumatologic inflammatory autoimmune diseases and
inflammatory bowel disease. Secondary objectives included the assessment of the
clinical relevance of the provided data and comparison of initial and post-
authorization data.
Methods: Initial and post-authorization data were extracted from the European Pub-
lic Assessment Reports and the latest versions of Summary of Product Characteristics
using publicly available documents on the European Medicines Agency's website.
Four sections were categorized regarding pregnancy outcomes: pre-clinical/animal
studies, human female fertility, pregnancy-related outcomes and congenital mal-
formations in the human fetus. Three sections were categorized regarding lactation
outcomes: pre-clinical/animal studies, excretion in human breast milk and absorption
in children through breastfeeding. The clinical applicability of each category was
scored by specified criteria, based on scientific literature, and further as defined by
the authors.
Results: For the 16 included biologics, post-authorization data were delivered only
for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining
biologics limited data on pregnancy and lactation during the post-marketing period of
2–21 years were available.
Conclusions: In this article several suggestions are provided for improving a multi-
disciplinary approach to these issues. The initiation of suitable registries by marketing
authorization holders and data transparency for clinicians and academics are highly
endorsed.
The authors confirm that no Principal Investigator for this paper was involved, as no patients
have participated in the study.
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1 | INTRODUCTION
Biologics are widely used in rheumatologic and gastroenterological
inflammatory autoimmune diseases. Their use in women of childbear-
ing potential is expected and subsequently detailed information on
the impact of these drugs on reproduction is therefore of utmost
importance.1
In Europe, the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) and the European Medicines Agency (EMA)
established rules to report on the reproductive safety of (approved)
drugs. These rules include the ICH-S5 guideline (1993, discusses
detection of toxicity to reproduction mostly in preclinical/animal stud-
ies), the ICH-S6 guideline (2011, recommends a basic framework for
the preclinical safety evaluation of biotechnology-derived pharmaceu-
ticals), the EMA “Guideline on the exposure to medicinal products
during pregnancy: Need for post-authorisation data” (2006) and the
“Guideline on risk assessment of medicinal products on human repro-
duction and lactation: from data to labelling” (2009).2-10
All these guidelines provide a minimum framework for the phar-
maceutical industry to perform pregnancy- and fertility-related studies
before and after registration.
Our first objective was to investigate the data on pregnancy and
lactation made publicly available by pharmaceutical companies at the
time and after marketing authorization in Europe of biologics for the
indications of rheumatologic and inflammatory bowel diseases. Sec-
ondary objectives included the assessment of the clinical relevance of
the provided data and comparison of the initial provided data to post-
authorization data. It should be noted that this study is not a review
of the scientific literature from published papers.
2 | MATERIALS AND METHODS
2.1 | Inclusion criteria
The inclusion criteria for the investigated biologics were:
• Approved by EMA from 1 January 1999 to 31 December 2018.
• Indicated for rheumatologic or inflammatory bowel diseases.
Initial available data at the time of authorization for the
selected biologicals were investigated. The data were extracted by
one investigator (N.G.) from the oldest publicly accessible “Initial
scientific discussions” in the European Public Assessment Reports
(EPARs) for each biological from the EMA official website.11 The
extracted information used in these comparisons is from the
sections in the initial dossiers discussed in the EPARs called
“Reproduction Toxicity”, “Toxico-pharmacological aspects” and
“Toxicokinetics”.12-28
The data added during the post marketing period were extracted
from the latest versions (to 7 May 2019) of the Summary of Product
Characteristics (SmPCs). The additional post-marketing data were
considered as the data related to pregnancy and/or lactation not men-
tioned in the initial dossiers but mentioned in the latest version of
SmPCs in the sections “4.6 Fertility, pregnancy and lactation” and “5.3
Preclinical safety data”.29-44
2.2 | Pregnancy information sections
The provided information was categorized as follows: (a) pre-
clinical/animal studies, (b) human female fertility, (c) pregnancy-related
outcomes, (d) congenital malformations in the human fetus and
(e) recommendations regarding continuation and/or discontinuation
during pregnancy Table 1.
The data per category were considered adequate when they ful-
filled the following criteria (shown in green in Tables 2 and 3):
1. Pre-clinical/animal studies: When the requirements of the ICH-S5
and ICH-S6 guidelines are fulfilled during the pre-marketing
period.6,8
2. Human female fertility: When data is provided on evaluation
of human female fertility by measuring effects on
What is already known about this subject
• At the time of launching biologics the effects on
reproduction/lactation are unknown although many
patients that receive these drugs are of reproductive age.
Because the effects are unknown, pregnancy during the
use of these drugs is discouraged. It is expected that after
launch pharmaceutical companies will actively update the
results of pregnancy/lactation outcomes.
What this study adds
• Our study gives a perspective on the pre- and post-
authorisation data on pregnancy/lactation provided for
different biologics at the same indication range. It shows
the differences between regulatory and clinical
approaches to this issue. It also creates a paradigm for
future studies of optimizing regulations regarding (contra)
indication of biologics during pregnancy/lactation.
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hypothalamic/pituitary gonadal function, as well as effects on the
reproductive organs/tissues, eg, by measuring serum
prolactin, Follicle-Stimulating Hormone (FSH), Luteinizing Hor-
mone (LH), progesterone, oestrogen levels and thyroid function.5
3. Pregnancy-related outcomes: When prospective data on human
pregnancy outcomes, with the exception of congenital mal-
formations (which are considered under (d)), are provided.
a. During the pre-marketing period, adequacy is considered as
delivering the results of unplanned pregnancies during clinical
trials in initial dossiers.
b. In the post-marketing period adequacy is considered as
reflecting information from spontaneous reports and publica-
tions in the literature on exposed pregnancy outcomes in the
most up to date SmPC, additional to the data delivered in the
initial dossier.4 Retrospective data are considered as supportive
information but not adequate.
4. Congenital malformations in the human fetus:
a. When during the pre-marketing period the results of unplanned
pregnancies are specifically mentioned regarding congenital
malformations.
b. When during the post-marketing period at least 300 pregnan-
cies exposed during the first trimester are prospectively studied
and a clear description of the incidences and type of congenital
malformations is given. The number of 300 patients is neces-
sary to be able to exclude the ≥10-fold risk of major congenital
malformations compared to the general population.5 In addition,
when the assessment of fetal and/or neonatal toxicity for
second/third trimester or pre-partum exposures are provided
based on available prospective or retrospective data, this is also
considered in this section as supportive information but not
adequate.28
When supportive information is only delivered by marketing
authorization holders (MAHs), this is shown in red in Tables 2 and
3. Orange colour in Tables 2 and 3 is considered as a symbol of
being for a short time (< 5 years) in the market, adequacy of data
for clinical management based on mentioned specific definitions,
wouldn't apply in these cases for post-marketing period.
2.3 | Lactation information sections
Regarding lactation the data was divided into three categories for
each biological: pre-clinical/animal studies, excretion in human breast
milk and absorption in children.
Data were considered adequate for clinical management when
they fulfilled the following criteria (shown in green in Tables 2 and 3),
stratified according to section:
1. Pre-clinical and/or animal studies: When the amounts and
timing of drug concentration in the mother's milk of studied
animals are provided.45 As larger molecules such as immuno-
globulins have more chance of being secreted into the milk due
to larger gaps in breast alveolar cells during the first postpartum
days, the timing of sampling is crucial for adequacy of informa-
tion in this regard.46 The statement of being
detectable/undetectable in mother's milk in animals without
exact amounts of excretion or the below the limit of quantita-
tion (BLQ) levels is considered as supportive information but
not adequate (transparency issue).
2. Excretion in human breast milk: When the concentration of the
active substance in human milk is estimated.5
TABLE 1 Provided clinical data and subsequent SmPC
recommendations on the use of adalimumab, certolizumab pegol,
etanercept and infliximab during pregnancy
Biological Data
Latest SmPC
recommendations
Adalimumab 2100 prospectively
collected exposed
pregnancies, no
increased rate of
malformations or
other unfavourable
outcomes*
“Adalimumab should
only be used
during pregnancy if
clearly needed.”
Certolizumab pegol 500 prospectively
collected exposed
pregnancies, no
increased rate of
malformations or
other unfavourable
outcomes*
“Cimzia should only
be used during
pregnancy if
clinically needed.”
Etanercept Two observational
cohorts, which
have shown two
different
conclusions
regarding major
birth defects
(adjusted OR 2.4
and 0.96 in 370
and 425
prospective cases,
respectively) but
no increased rate
of other
unfavourable
outcomes*
“Enbrel should only
be used during
pregnancy if
clearly needed.”
Infliximab 1100 prospectively
collected exposed
pregnancies, no
increased rate of
malformations but
increased risk for
secondary
outcomes**
“Infliximab should
only be used
during pregnancy if
clearly needed.”
*Unfavourable outcomes in this regard include spontaneous abortions,
minor birth defects, preterm delivery, birth size and serious or
opportunistic infections and no stillbirths or malignancies.
**Including Caesarean section, preterm birth, small for gestational age and
low birth weight.
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3. Absorption in children: When the amount of medicinal product
received by infants via milk is estimated based on the infant
dose as a percentage of the weight-adjusted maternal dose. If this
is <10% no additional studies are required. If the percentage of
weight-adjusted maternal dose exceeds 10%, breastfed infants'
plasmaconcentrations of the medicinal product, it should be stud-
ied and follow-up studies of the breastfed children should be
initiated.45,47
2.4 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the The International Union of Basic and
Clinical Pharmacology/BritishPharmacological Society (IUPHAR/BPS)
Guide to Pharmacology.
3 | RESULTS
Based on the inclusion and exclusion criteria the following 16 biologics
were included (named alphabetically):11-44
1. abatacept Abatacept (Orencia, Date of authorization: 21/05/
2007, Indications: Rheumatoid Arthritis (RA), polyarticular Juve-
nile Idiopathic Arthritis (pJIA), Psoriatic Arthritis (PsA), Mechanism
of action: T-cell inhibition ),
2. adalimumab (Humira, Date of authorization: 07/09/2003, Indica-
tions: Ankylosing Spondylitis (AS), Uveitis, Ulcerative Colitis (UC),
Psoriasis, PsA, Crohn's Disease (CD), pJIA, RA, Mechanism of
action: tumor necrosis factor (TNF) inhibition),
3. anakinra (Kineret, Date of authorization: 08/03/2002, Indication:
RA, Mechanism of action: Interleukin (IL)-1 inhibition),
4. belimumab (Benlysta, Date of authorization: 13/07/2011, Indica-
tion: Systemic Lupus Erythematosus, Mechanism of action: B-cell
inhibition),
5. canakinumab (Ilaris, Date of authorization: 23/10/2009, Indica-
tions: Periodic fever syndromes, Still's disease, Gouty arthritis,
Mechanism of action: IL-1 inhibition),
6. certolizumab pegol (Date of authorization: 01/10/2009, Indica-
tion: RA, Mechanism of action: TNF inhibition),
7. etanercept (Enbrel, Date of authorization: 02/02/2000, Indica-
tions: AS, pJIA, PsA, Psoriasis, RA, Mechanism of action: TNF
inhibition),
8. golimumab (Simponi, Date of authorization: 01/10/2009,
Indications: PsA, AS, UC, RA, Mechanism of action: TNF
inhibition),
9. infliximab (Remicade, Date of authorization: 13/08/1999, Indica-
tions: AS, RA, Psoriasis, CD, UC, PsA, Psoriasis, Mechanism of
action: TNF inhibition),
10. ixekizumab (Taltz, Date of authorization: 25/04/2016, Indica-
tions: Plaque psoriasis, PsA, Mechanism of action: IL-17
inhibition),
11. rituximab (MabThera, Date of authorization: 02/06/1998, Indica-
tions: Non-Hodgkin Lymphoma, Chronic B-Cell Lymphocytic Leu-
kemia, RA, Mechanism of action: B-cell depletion),
12. sarilumab (Kevzara, Date of authorization: 23/06/2017, Indica-
tion: RA, Mechanism of action: IL-6 inhibition),
13. secukinumab (Cosentyx, Date of authorization: 14/01/2015,
Indications: PsA, Psoriasis, AS, Mechanism of action: IL-17
inhibition),
14. tocilizumab (RoActerma, Date of authorization: 15/01/2009, Indi-
cations: RA, pJIA, Mechanism of action: IL-6 inhibition),
15. ustekinumab (Stelara, Date of authorization: 15/01/2009, Indica-
tions: Psoriasis, PsA, Crohn Disease, Mechanism of action: IL-12/
23 blockade),
16. vedolizumab (Entyvio, Date of authorization: 22/05/2014, Indica-
tions: UC, CD, Mechanism of action: T-cell inhibition).
The results for initial data based on the definitions of adequacy
criteria in each section are shown in Table 2 (for more detailed infor-
mation see Supporting Information Table S2A):
1. Pregnancy data
a. Pre-clinical and/or animal studies:
For abatacept, adalimumab, anakinra, belimumab, canakinumab,
certolizumab pegol, etanercept, golimumab, infliximab,
ixekizumab, sarilumab, secukinumab, tocilizumab, ustekinumab
and vedolizumab, animal studies on reproduction were per-
formed during the pre-marketing period. For rituximab, no
reproductive pre-clinical/animal studies were mentioned to
have been performed before marketing authorization. All the
biologicals except rituximab therefore scored as adequate in
this section. No additional data were provided in the most up to
date SmPC of adalimumab, anakinra, belimumab, canakinumab,
certolizumab pegol, etanercept, golimumab, infliximab,
ixekizumab, secukinumab, tocilizumab, ustekinumab and
vedolizumab. Data for embryo-fetal development studies for
abatacept are provided in the latest version of the SmPC and do
not show “unfavorable effects” (the definition of “unfavorable
effects” is not given). Studies were done in cynomolgus mon-
keys for rituximab during the post-marketing period which
show depletion of B cells in peripheral blood and in lymphoid
tissue in the fetus.12-44
b. Human female fertility:
Pre-marketing period: For abatacept, adalimumab, anakinra,
belimumab, canakinumab, certolizumab pegol, etanercept,
golimumab, infliximab, ixekizumab, rituximab, sarilumab,
secukinumab, tocilizumab, ustekinumab and vedolizumab no
studies were performed to evaluate effects on human female
fertility.12-28
Post-marketing period: No additional fertility studies to investi-
gate effects on women's fertility were performed for the 16 bio-
logicals. Consequently, none of them scored as adequate in this
section.29-44
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c. Pregnancy-related outcomes:
Pre-marketing period: Results of unplanned pregnancies during
clinical trials were provided for abatacept, ixekizumab, sarilumab
and secukinumab (for detailed information see Supporting Infor-
mation Table S2A). For belimumab 60 unplanned pregnancies
during clinical trials occurred. The results of these unplanned
pregnancies were not provided. For adalimumab, anakinra, can-
akinumab, certolizumab pegol, etanercept, golimumab,
infliximab, rituximab, tocilizumab, ustekinumab and vedolizumab
no information was provided on whether there were unplanned
pregnancies during the clinical trials.12-28
Post-marketing period: For abatacept, anakinra, belimumab,
canakinumab, golimumab, rituximab, secukinumab, tocilizumab,
ustekinumab and vedolizumab pregnancy-related studies are
not provided in the SmPC for the post-marketing
period.30-32,34-44 For adalimumab, certolizumab pegol,
etanercept and infliximab prospective studies were conducted,
including more than 300 followed pregnancies (for more details
see Supporting Information Table S2A).29-44
d. Congenital malformations in the human fetus:
Pre-marketing period: Congenital malformations in unplanned
pregnancies were not investigated during clinical development
of abatacept, adalimumab, anakinra, belimumab, canakinumab,
certolizumab pegol, etanercept, golimumab, infliximab,
ixekizumab, rituximab, sarilumab, tocilizumab, ustekinumab and
vedolizumab. For secukinumab congenital malformations were
investigated for unplanned pregnancies during clinical trials and
none were found, therefore none of these biologicals were
scored as adequate for clinical management in this section
except secukinumab.12-28
Post-marketing period: No prospective studies were performed
to investigate congenital malformations in pregnancies exposed
to abatacept, anakinra, belimumab, canakinumab, golimumab,
rituximab, secukinumab, tocilizumab, ustekinumab and
vedolizumab during the post-marketing period, and spontane-
ous reporting was relied on instead.29-44
Adalimumab, certolizumab pegol and etanercept initiated
registries regarding pregnancy-related outcomes and congenital
abnormality risk anticipation during the post-marketing period.
For infliximab one controlled observational study was
conducted during the post-marketing period. The results of
these studies are briefly mentioned in the latest SmPCs (see
the Appendix).36,38,39,43 These biologics scored as delivering
adequate data for clinical management in this section. Recom-
mendations have changed in the most updated SmPCs based
on these studies (Table 1).
The results for initial data regarding investigated three cate-
gories in lactation is shown in Table 3. Based on the defini-
tions of adequate for clinical management in each section,
each investigated biological was scored as bellow (for
detailed comparison please see Supporting Information
Table S3A in the Appendix):
2. Lactation data
a. Pre-clinical and/or animal studies:
The results of drug concentration in breast milk in pre-
clinical/animal studies during the pre-marketing period were
provided for following biologicals:
• Abatacept: In lactating rats, the milk-to-serum ratios for
abatacept were 0.08-0.09. Abatacept was also detected in
pup sera but the origin of this activity is unclear (from mater-
nal milk or from maternal circulation). The lower limit of
quantification (LLQ) for abatacept in rat milk was
3.0 ng/mL. The calibration range was in the range
1–40 ng/mL.28
• Belimumab: This was detected in milk from female monkeys
administered 150 mg/kg every 2 weeks. The exact amounts
of detected drug are not provided.25
• Certolizumab pegol: Administration of the full antibody
resulted in exposure of rats' offspring via milk. Milk transfer
was negligible.24
• Golimumab: This was found in monkey breast milk, but
the concentrations were low (4 μg/mL in the 50 mg/kg
treatment group) and were approximately 350-fold lower
than maternal serum concentrations during the lactation
period.22
• Ixekizumab: This was excreted at low levels in the milk of
cynomolgus monkeys. The maternal milk to maternal
serum concentration ratios in cynomolgus monkeys were
0.0018 and 0.0011 for doses of 5 mg/kg and 50 mg/kg,
respectively on postpartum day (PPD) 14. Mean
Ixekizumab milk concentrations decreased over time to
PPD 56.14
• Ustekinumab: Excretion at low levels in cynomolgus mon-
keys was detected, but the exact amounts of detected drug
and timing of sample acquisition are not provided.17
• Vedolizumab: Low levels (<300 mcg/L) on day 28 postpartum
in breast milk in 3/11 animals at dosage of 100 mg/kg. Not
detected in the breast milk at 10 mg/kg.16
Timing of sample acquisition was only mentioned for
ixekizumab and vedolizumab, therefore based on mentioned
criteria these biologicals scored as adequate for pre-
clinical/animal studies delivery criteria. No animal studies
were performed to measure drug secretion into mother's
milk in initial trials of adalimumab, anakinra, canakinumab,
etanercept, infliximab, rituximab, sarilumab, secukinumab and
tocilizumab, therefore data for these biologicals scored as
not adequate for initial data on pre-clinical/animal
studies.12-28During the post-marketing period drug concentra-
tions in mother's milk in animal studies were provided for
etanercept (excreted in rat milk and in the serum of pips, the
exact amounts and timing of detected drug are not provided)
and rituximab (detectable in milk from lactating monkeys, the
exact amounts and timing of detected drug are not provided).
For adalimumab, anakinra, canakinumab, infliximab, ixekizumab,
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sarilumab, secukinumab and tocilizumab, there are no data
available in this regard.29-44
b. Excretion in human breast milk:
Pre-marketing period: The concentration of the active sub-
stance/metabolites in human milk was not determined for
any of the investigated biologicals before marketing authori-
zation.12-28
Post-marketing period: The concentration of the active sub-
stance/metabolites in human milk was estimated for
adalimumab (a literature review by the manufacturer indi-
cated low excretion of adalimumab in breast milk) and
certolizumab pegol (minimal transfer to breast milk in 17 lac-
tating women) during the post-marketing period. None of
other investigated biologicals delivered data in this regard
during the post-marketing period.29-44
c. Absorption in children:
Pre-marketing period: The estimated amount of medicinal prod-
uct received by infants via milk was not calculated for any of
the investigated biologicals before marketing authorization.12-28
Post-marketing period: The amount of medicinal product
received by infants via milk was estimated for certolizumab
pegol (0.04-0.30%) and adalimumab (0.1-1%) based on the
infant dose as a percentage of the weight-adjusted maternal
dose. In both these amounts were <10% and therefore no addi-
tional studies were required based on mentioned criteria (see
Materials and Methods). No other investigated biologicals deliv-
ered data in this regard during the post-marketing period.29-44
All together, initial data could not be scored as adequate
for clinical management for the investigated biologics in any
of the categories for any of the investigated biologics other
than animal studies on lactation for abatacept, belimumab,
certolizumab pegol, golimumab, ixekizumab, ustekinumab and
vedolizumab (seven out of 16 investigated biologics). Only
adalimumab and certolizumab pegol provided adequate data
during the post-marketing period on excretion in human
breast milk and absorption in children. These are also the only
two biologics approved by the EMA for use during lactation.
The most recent dossier on adalimumab does not provide
data on concentration of adalimumab in breast milk in animal
studies.39,43
4 | DISCUSSION
Despite being on the market for years, the data on pregnancy and lac-
tation outcomes are still not adequately delivered for most of the
investigated biologicals. The clinical relevance of most of these biolog-
icals could not be scored as sufficient for making an evidence-based
decision in practice. Comparing the pre- and post-marketing data
shows in general inadequate efforts for providing information in this
regard. Clinicians therefore have to make decisions without
supporting data in this regard, even after years of marketing authori-
zation. This can lead to unnecessary discontinuation of biologics or
unnecessary termination of pregnancy. At the time of marketing
authorization the only available data that can be used to estimate a
risk during pregnancy are animal data and data on unplanned pregnan-
cies during clinical trials. As pointed out in ICH-S6 guideline,2 repro-
duction toxicity studies in animals should only be performed if the
product of interest is pharmacologically active in the animal species,
as most if not all of the adverse effects seen are due to the pharmaco-
logical effect. For biologicals, the species used is often the monkey, as
this is the only relevant species in most cases due to specificity of the
compound. A lack of adverse effects in the monkey does not translate
into a guarantee of safety in humans, although it does provide some
reassurance. However, adverse effects that can be related to the
mechanism of action of the biological on embryo-fetal development in
the monkey can be seen as a clear signal for risk during human preg-
nancy. Further clinical data are required in any case to provide a clear
understanding of the risk and allow clinical management of patients
with a reproductive wish during the treatment of autoimmune inflam-
matory diseases with biologics.
The problem regarding lack of adequate pregnancy/lactation data
extends even further, since after years of being in the market limited
initiatives from the pharmaceutical companies have been taken for col-
lecting prospective data during pregnancy or publishing the available
data from their databases. Post-marketing data on pregnancy exposure
submitted by the marketing authorization holders (such as periodic
safety update reports) are mostly retrospective and inconclusive. Risk
minimization measures are inadequate and most of the time ineffective.
However, for adalimumab, certolizumab pegol and etanercept, pharma-
ceutical companies updated information and as a result adjustments
were made in their SmPCs (AbbVie, one of the sponsors for the
adalimumab pregnancy exposure registry, and Amgen, the main sponsor
of the etanercept pregnancy registry cohort study, both conducted by
the Organization of Teratology Information Specialists, UCB Pharma as
the main sponsor of the CRIB and CRADLE pharmacokinetic studies).48
If initiating registries and follow-up studies about exposure to biologi-
cals during pregnancy and/or lactation were mandatory, the same could
be done by other MAHs.
After reviewing all our data it seems that intensified collabora-
tion between healthcare providers, academics and MAHs to
enhance research on reproduction/lactation at an early stage of
biological development is needed. This responsibility includes all
stakeholders.
4.1 | Suggestions for future legalisation
procedures
In view of the current non-optimal situation, we suggest the
following:
4.2 | Pre-clinical investigations:
1. Investment in the development of human-relevant technologies
should be made in addition to existing animal studies. From
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human-relevant technologies we can refer to micro-engineered
models of the human placental barrier to simulate and investigate
drug transfer from maternal to fetal circulation, in vitro perfusion
studies of human placentas obtained immediately after delivery
and bioluminescent imaging of drug efflux activity at the blood-
placenta barrier. From a regulatory point of view, this evidence
may or may not change the benefit-risk assessment of the product,
but it would be useful when clinical data are not available. Existing
technologies can be used in this regard, eg, conducting cell biology
research to investigate binding and functional consequences for
different cell types in the human placenta.49-54
2. More focus is needed on the timing of the transfer of the biological
during lactation. Samples should be taken within the first week of
lactation and at several time points afterwards to investigate
the hypothesis that transfer to breast milk is only relevant for
colostrum.
4.3 | During clinical trials:
1. Unplanned pregnancies during randomised controlled trials should
be documented, each case should be followed up and appropriate
documentation of the outcomes should be amended (taking into
consideration that many women make a choice for elective abor-
tion). This provides stronger evidence than retrospective data in
initial states and should be performed in addition to gathering pro-
spective post-marketing data.
2. The children of those unplanned pregnancies should be
followed up and their development and growth documented.
Data on transfer to breast milk should be collected when
available.
4.4 | Post-marketing period:
1. The minimum data to be delivered by the marketing authorisation
holder about pregnancy/lactation should be defined precisely. This
should be collected as additional pharmacovigilance activity next
to spontaneous reporting, with strict milestones regarding submis-
sion of data.
2. The initiation of pregnancy registries should be imposed on mar-
keting authorisation holders as an additional pharmacovigilance
activity (collecting prospective data), with milestones on interim
reporting (this point can also be applied to the pre-marketing
period).
3. Missing pregnancy/lactation data should not be a routine state-
ment in Risk Management Plans (RMPs) and there should be
amendments for planning an active approach in this regard.
4. Academic researchers should be allowed to have access to data on
biological exposure during pregnancy/lactation from clinical trials
and post-marketing data collected by pharmaceutical companies.
Additional cooperation between databases of medicines regulatory
networks such as Eudravigilance and databases of pharmaceutical
companies should be facilitated.
MAHs and regulatory authorities should reflect all the available
data about pregnancy and lactation that is clearly related to the use of
the biological in detail and numerically in SmPC and EPAR public
assessment reports. Limiting the given information to conclusions and
interpretations should be therefore avoided.
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